Zomedica Corp. (ZOMDF)
OTCMKTS · Delayed Price · Currency is USD
0.09705
+0.002775 (2.94%)
At close: Nov 10, 2026
Zomedica Financials Overview
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 38.68 | 32.03 | 27.29 | 25.19 | 18.93 | 4.13 |
Revenue Growth | 31.33% | 17.39% | 8.33% | 33.05% | 358.02% | - |
Gross Profit Gross Profit Growth | 24.74 | 21.68 | 19.09 | 17.32 | 13.47 | 3.05 |
Operating Income Operating Income Growth | -17.57 | -28.52 | -35.03 | -31.59 | -21.92 | -21.37 |
Net Income Net Income Growth | -16 | -81.86 | -46.98 | -34.53 | -17.02 | -50.42 |
Earnings Per Share EPS Growth | -0.02 | -0.08 | -0.05 | -0.04 | -0.02 | -0.05 |
EPS Growth | - | - | - | - | - | - |
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Diagnostics Diagnostics Growth | 2.8 | 2.43 | 1.38 | 0.39 | 0.13 |
Therapeutics Devices Therapeutics Devices Growth | 26.2 | 24.85 | 23.81 | 18.54 | 4.01 |
Development Services Development Services Growth | 3.03 | - | - | - | - |
Total Total Growth | 32.03 | 27.29 | 25.19 | 18.93 | 4.13 |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 40.13 | 53.26 | 71.35 | 90.5 | 115.09 | 194.95 |
Total Debt Total Debt Growth | 1.65 | 2.18 | 1.81 | 2.73 | 1.74 | 1.38 |
Net Cash (Debt) Net Cash Growth | 38.48 | 51.07 | 69.54 | 87.77 | 113.35 | 193.57 |
Net Cash Growth | -24.21% | -26.56% | -20.77% | -22.57% | -41.44% | 221.96% |
Net Cash Per Share Net Cash Per Share Growth | 0.04 | 0.05 | 0.07 | 0.09 | 0.12 | 0.20 |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -11.48 | -17.65 | -23.63 | -15.98 | -11.67 | -14.28 |
Capital Expenditures CapEx Growth | -0.45 | -0.57 | -5.21 | -11.34 | -2.55 | -0.15 |
Free Cash Flow Free Cash Flow Growth | -11.92 | -18.22 | -28.84 | -27.31 | -14.22 | -14.42 |
Free Cash Flow Growth | - | - | - | - | - | - |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 63.96% | 67.68% | 69.95% | 68.76% | 71.15% | 73.89% |
Operating Margin | -45.43% | -89.04% | -128.38% | -125.44% | -115.81% | -517.15% |
Pretax Margin | -41.71% | -256.43% | -174.23% | -142.38% | -102.38% | -501.26% |
Profit Margin | -41.35% | -255.57% | -172.19% | -137.10% | -89.88% | -1220.01% |
FCF Margin | -30.82% | -56.87% | -105.71% | -108.45% | -75.12% | -348.97% |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Nov '26 Nov 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PS Ratio | 2.39 | 3.11 | 4.31 | 7.79 | 8.44 | 72.67 |